Immune Design: Corporate Overview (Immune Design) - Jul 10, 2016 - Anticipated analysis of initial patients in P2 trial (NCT02609984) of CMB305 in combination with atezolizumab for soft tissue sarcoma in Q4 2016; Anticipated data from P1 trial (NCT02387125) for locally advanced, relapsed, or metastatic cancer at ASCO (Jun 2-6, 2017); Anticipated early BLA filing in soft tisue sarcoma in Q4 2018
Anticipated BLA • Anticipated P1 data • Anticipated P2 data • Oncology • Sarcoma
|